Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jun;8(3):301-303.
doi: 10.21037/gs.2019.04.11.

TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome

Jianliang Man  1 , Norman Nicolson  1 , Courtney Gibson  1 , Tobias Carling  1
Affiliations
Editorial

TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome

Jianliang Man et al. Gland Surg. 2019 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer 2019;108:41-9. 10.1016/j.ejca.2018.12.003 - DOI - PubMed
    1. Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer. Trends Mol Med 2013;19:125-33. 10.1016/j.molmed.2012.11.006 - DOI - PubMed
    1. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013;152:390-3. 10.1016/j.cell.2013.01.010 - DOI - PubMed
    1. Kim NW, Piatyszek MA, Prowse KR, et al. Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science 1994;266:2011-5. 10.1126/science.7605428 - DOI - PubMed
    1. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10. 10.1530/ERC-13-0210 - DOI - PMC - PubMed